A Phase 4 interventional study of Aripiprazole and Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine) in Metabolic Syndrome and Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 30 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing aripiprazole in Metabolic Syndrome — none open to participants now, none under way, none of them phase 3. Aripiprazole · Metabolic Syndrome.
Among the 10 studies testing aripiprazole in Metabolic Syndrome, this one is the 4th largest by enrollment, is one of 2 that started in 2007, is one of 6 in phase 4, and was the 4th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →None of the 10 studies testing aripiprazole in Metabolic Syndrome is open now. The open studies under Metabolic Syndrome, anywhere →
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2007.
This study's enrollment of 125 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 57 across the 10 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 9 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 18 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 2 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing aripiprazole in Metabolic Syndrome, from their registry updates:
This tab as a report to print or save as PDF → With an account.
258 patients who have been treated for at least 3 months with oral olanzapine, risperidone or quetiapine in the treatment of schizophrenia and currently presenting with metabolic syndrome, will be randomized to: i) aripiprazole for 16 weeks, with flexible dosing within a range of 10 to 30 mg once daily (QD); or ii) continue for 16 weeks on the same atypical antipsychotic treatment prior to the study enrollment.
Inclusion Criteria:
Patients:
Drug: Aripiprazole
Drug: Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
Tablets, Oral, 5 to 30 mg, once daily, 16 weeks
Also known as: Abilify, BMS-337039
Tablets, Oral, According to summary of product characteristics (SmPC)
Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (HDL) Cholesterol at Week 16
Non-HDL cholesterol was calculated as fasting Total Cholesterol minus fasting HDL Cholesterol.
Time frame: Baseline, Week 16
Number of Participants Remaining on Metabolic Syndrome at Week 16
Metabolic syndrome is defined as the presence of at least 3 out of the following Adult Treatment Panel III-A (ATP III-A) criteria (all of which are to be assessed at the same visit): waist \>102 cm in males, \>88 cm in females; blood pressure (BP) systolic BP ≥130 or diastolic BP ≥85 mm Hg; fasting HDL \<40 mg/dL in males, \<50 mg/dL in females; fasting triglycerides ≥150 mg/dL; fasting glucose ≥100 mg/dL, and/or the start of a treatment for any of the parameters of metabolic syndrome during the course of the study.
Time frame: Week 16
Mean Percent Change From Baseline in Fasting Lipid Parameters Through Week 16
Mean percent change from baseline in total cholesterol, low-density lipoprotein (LDL), HDL, and triglycerides.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16
Mean Change From Baseline for Fasting Glucose Levels Through Week 16
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16
Mean Change From Baseline in Body Weight Through Week 16
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16
Median Change From Baseline in Body Mass Index (BMI) Through Week 16
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16
Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale Through Week 16
A CGI-S assessment (a 7-point scale to evaluate the severity of symptoms) was performed at baseline (1=normal; 7=among the most extremely ill patients). A decrease in value indicates improvement.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16
Mean Change From Baseline in Subjective Well-Being Under Neuroleptics Scale (SWN-short Form) Through Week 16
The SWN-short form is a 20-item self-report instrument that measures subjective well-being under neuroleptics. 10 positive and 10 negative items cover 5 health domains (subscales) (4 items each): emotional regulation, self-control, mental functioning, social integration, and physical functioning. Individual scores range from 1 (not at all) to 6 (very much). With negative item scores being reversed, Subscale scores range from 4 to 24 and Total score ranges from 20 to 120.
Time frame: Baseline, Week 4, Week 8,Week 12, Week 16
Mean Change From Baseline in the Impact of Weight on Quality of Life (IWQoL-Lite) Scale Through Week 16
IWQoL-Lite is a 31-item self-report inventory to assess the impact of weight on quality of life among patients with obesity. Subscales include: Physical Function, Self Esteem, Sexual Life, Public Distress and Work. The rescaled IWQoL-Lite Total Score is determined by the sum of the 1 to 5 scores on all 31 items and rescaling this sum to a 0-100 scoring with 0=the poorest and 100=the best quality of life. A change of 7.8 to 12.0 points on the rescaled IWQoL-Lite Total Score=a meaningful improvement. A change of -4.5 to -7.6 on the rescaled IWQoL-Lite Total Score=a meaningful deterioration.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16
| Milestone | Control Group | Aripiprazole |
|---|---|---|
| Started | 26 | 26 |
| Randomized sample | 26 | 26 |
| Safety sample | 26 | 25 |
| Completed | 24 | 23 |
| Not completed | 2 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Subject withdrew consent | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Subject no longer met study criteria | 0 | 1 |
| Withdrew: Other known cause | 0 | 1 |
Non-HDL cholesterol was calculated as fasting Total Cholesterol minus fasting HDL Cholesterol.
| percent change | Control Group | Aripiprazole |
|---|---|---|
| Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (HDL) Cholesterol at Week 16 | 10.06 ± 4.35 | -2.3 ± 3.85 |
Metabolic syndrome is defined as the presence of at least 3 out of the following Adult Treatment Panel III-A (ATP III-A) criteria (all of which are to be assessed at the same visit): waist \>102 cm in males, \>88 cm in females; blood pressure (BP) systolic BP ≥130 or diastolic BP ≥85 mm Hg; fasting HDL \<40 mg/dL in males, \<50 mg/dL in females; fasting triglycerides ≥150 mg/dL; fasting glucose ≥100 mg/dL, and/or the start of a treatment for any of the parameters of metabolic syndrome during the course of the study.
| participants | Control Group | Aripiprazole |
|---|---|---|
| Number of Participants Remaining on Metabolic Syndrome at Week 16 | 22 | 16 |
Mean percent change from baseline in total cholesterol, low-density lipoprotein (LDL), HDL, and triglycerides.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
A CGI-S assessment (a 7-point scale to evaluate the severity of symptoms) was performed at baseline (1=normal; 7=among the most extremely ill patients). A decrease in value indicates improvement.
No measurements were reported for this outcome.
The SWN-short form is a 20-item self-report instrument that measures subjective well-being under neuroleptics. 10 positive and 10 negative items cover 5 health domains (subscales) (4 items each): emotional regulation, self-control, mental functioning, social integration, and physical functioning. Individual scores range from 1 (not at all) to 6 (very much). With negative item scores being reversed, Subscale scores range from 4 to 24 and Total score ranges from 20 to 120.
No measurements were reported for this outcome.
IWQoL-Lite is a 31-item self-report inventory to assess the impact of weight on quality of life among patients with obesity. Subscales include: Physical Function, Self Esteem, Sexual Life, Public Distress and Work. The rescaled IWQoL-Lite Total Score is determined by the sum of the 1 to 5 scores on all 31 items and rescaling this sum to a 0-100 scoring with 0=the poorest and 100=the best quality of life. A change of 7.8 to 12.0 points on the rescaled IWQoL-Lite Total Score=a meaningful improvement. A change of -4.5 to -7.6 on the rescaled IWQoL-Lite Total Score=a meaningful deterioration.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole | — | 0/25 (0%) | 9/25 (36%) |
| Control Group | — | 0/26 (0%) | 2/26 (7.7%) |
| Event | Aripiprazole | Control Group |
|---|---|---|
| HeadacheNervous system disorders | 4/25 | 0/26 |
| AnxietyPsychiatric disorders | 3/25 | 0/26 |
| InsomniaPsychiatric disorders | 3/25 | 0/26 |
| NauseaGastrointestinal disorders | 3/25 | 0/26 |
| RashSkin and subcutaneous tissue disorders | 2/25 | 0/26 |
| Blood cholesterol increasedInvestigations | 0/25 | 2/26 |
| Age, Continuous(years) | Control Group | Aripiprazole | Total |
|---|---|---|---|
| Mean | 40.7 ± 10.47 | 43.9 ± 11.16 | 42.3 ± 10.84 |
| Sex: Female, Male(Participants) | Control Group | Aripiprazole | Total |
|---|---|---|---|
| Female | 13 | 11 | 24 |
| Male | 13 | 15 | 28 |
| Race/Ethnicity, Customized(participants) | Control Group | Aripiprazole | Total |
|---|---|---|---|
| White | 23 | 26 | 49 |
| Black/African American | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 |
| Other | 1 | 0 | 1 |
| Body Mass Index (BMI) category(Participants) | Control Group | Aripiprazole | Total |
|---|---|---|---|
| < 30 kg/m2 | 7 | 13 | 20 |
| >=30 kg/m2 | 19 | 13 | 32 |
| Waist Circumference Category(participants) | Control Group | Aripiprazole | Total |
|---|---|---|---|
| ≤ 102 cm for Men/ ≤ 88 cm for Women | 1 | 2 | 3 |
| > 102 cm for Men/ > 88 cm for Women | 25 | 24 | 49 |
| Body Mass Index (BMI)(kg/m2) | Control Group | Aripiprazole | Total |
|---|---|---|---|
| Mean | 31.45 (19.0 to 42.8) | 31.31 (25.1 to 49.1) | 31.38 (19.0 to 49.1) |
| Fasting Non-High Density Lipoprotein (HDL) Cholesterol(mg/dL) | Control Group | Aripiprazole | Total |
|---|---|---|---|
| Mean | 173.1 (118 to 267) | 169.0 (110 to 268) | 171.0 (110 to 268) |
| Waist Circumference(cm) | Control Group | Aripiprazole | Total |
|---|---|---|---|
| Mean | 107.1 (90 to 136) | 107.1 (91 to 134) | 107.1 (90 to 136) |
1 further baseline measures are reported on the registry.
Ran from Nov 2007 to primary completion in Mar 2009, 16 months.
Results were first posted in Jul 2010, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →